Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.

作者: Marwan Fakih

DOI: 10.2147/OTT.S3026

关键词:

摘要: Colorectal cancer continues to be an important public health concern, despite improvements in screening and better systemic chemotherapy. The integration of targeted therapies the treatment colon has resulted significant efficacy outcomes. Angiogenesis is for tumor growth metastasis target new biological agents. Bevacizumab a humanized recombinant antibody that prevents vascular endothelial factor (VEGF) receptor binding, inhibits angiogenesis growth. addition bevacizumab fluoropyrimidine-based chemotherapy, with or without irinotecan oxaliplatin, both first- second-line metastatic colorectal cancer, significantly increased median progression-free survival overall select randomized phase III studies. Ongoing studies are evaluating role adjuvant cancer. Common toxicities associated include hypertension, bleeding episodes, thrombotic events. This review will focus on paradigm management its side effects.

参考文章(87)
Herman D. Suit, Sergey V. Kozin, Daniel J. Hicklin, Yves Boucher, Rakesh K. Jain, Peter Bohlen, Vascular Endothelial Growth Factor Receptor-2-blocking Antibody Potentiates Radiation-induced Long-Term Control of Human Tumor Xenografts Cancer Research. ,vol. 61, pp. 39- 44 ,(2001)
Richard L. Gamelli, Peter J. Polverini, Michael V. Volin, Alisa E. Koch, Nicholas N. Nissen, Luisa A. DiPietro, Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. American Journal of Pathology. ,vol. 152, pp. 1445- 1452 ,(1998)
R M Shaheen, S A Ahmad, W Liu, N Reinmuth, Y D Jung, W W Tseng, K E Drazan, C D Bucana, D J Hicklin, L M Ellis, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors British Journal of Cancer. ,vol. 85, pp. 584- 589 ,(2001) , 10.1054/BJOC.2001.1936
J Tol, M Koopman, NF Antonini, H Sinnige, FAA Valster, JJ Braun, AJ ten Tije, L Mol, JHJM van Krieken, C Punt, Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) Journal of Clinical Oncology. ,vol. 26, ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.LBA4011
Marc A. Shuman, K. Jin Kim, Ostap Melnyk, Vascular Endothelial Growth Factor Promotes Tumor Dissemination by a Mechanism Distinct from Its Effect on Primary Tumor Growth Cancer Research. ,vol. 56, pp. 921- 924 ,(1996)
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
K. Margolin, M. S. Gordon, E. Holmgren, J. Gaudreault, W. Novotny, G. Fyfe, D. Adelman, S. Stalter, J. Breed, Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data Journal of Clinical Oncology. ,vol. 19, pp. 851- 856 ,(2001) , 10.1200/JCO.2001.19.3.851
A. Grothey, L. L. Hart, K. M. Rowland, R. H. Ansari, S. R. Alberts, N. M. Chowhan, A. Shpilsky, H. S. Hochster, Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial Journal of Clinical Oncology. ,vol. 26, pp. 4010- 4010 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4010
K Jin Kim, Bing Li, Jane Winer, Mark Armanini, Nancy Gillett, Heidi S Phillips, Napoleone Ferrara, None, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature. ,vol. 362, pp. 841- 844 ,(1993) , 10.1038/362841A0
H DVORAK, Discovery of vascular permeability factor (VPF). Experimental Cell Research. ,vol. 312, pp. 522- 526 ,(2006) , 10.1016/J.YEXCR.2005.11.026